Eloralintide weight loss study for adults with excess weight and type 2 diabetes
Tests eloralintide against placebo for weight loss in adults with type 2 diabetes.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Ansan-si, Guri-si, Gwangju, Seongnam, and Seoul, South KoreaSee the 5 sitesAlso in 12 other countries, 138 sites
- Trial code
- NCT07282600
- EU 2025-523658-15-00
- U1111-1331-1119
- Registry title
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,035 people, planned
- Started
- 15 Dec 2025
- Expected to end
- Feb 2028
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Eloralintide
- Placebo
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and a BMI of 27 kg/m2 or more. It compares eloralintide with placebo for weight loss.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with overweight or obesity (BMI ≥ 27 kg/m2).
- Earlier treatment
- Must be on stable treatment for type 2 diabetes for at least 90 days before screening. Must not have taken amylin analogs, GLP-1 receptor agonists, GIP/GLP receptor agonists or insulin, or weight-loss medicines or remedies, within 90 days before screening.
Main reasons for not taking part
- Type 1 diabetes
- Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
- Class IV congestive heart failure (New York Heart Association)
- Body weight change of 5% or more in the 90 days before screening
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Have type 2 diabetes
- Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
- Have a BMI ≥ 27 kg/m2
- Have a stable body weight (<5% body weight change) for 90 days prior to screening
Who cannot take part
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening
- Have type 1 diabetes
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken any of the following antihyperglycemic medications within 90 days before screening:; amylin analogs; glucagon-like peptide-1 (GLP-1) receptor agonists; glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or; insulin
Where in South Korea
Also in 12 other countries, 138 sites
- Korea University Ansan HospitalAnsan-si, South KoreaContact: NANHEE KIM (principal investigator)Taking people
- Hanyang University Guri HospitalGuri-si, South KoreaContact: Chang Beom Lee (principal investigator)Taking people
- Chosun University HospitalGwangju, South KoreaContact: Sang Yong Kim (principal investigator)Taking people
- Seoul National University Bundang HospitalSeongnam, South KoreaContact: Soo Lim (principal investigator)Taking people
- Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Byung Wan Lee (principal investigator)Taking people
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
The 5 groups in the trial
- Eloralintide Dose 1Treatment being tested
Participants will receive eloralintide subcutaneously (SC)
Treatment: Eloralintide
- Eloralintide Dose 2Treatment being tested
Participants will receive eloralintide SC
Treatment: Eloralintide
- Eloralintide Dose 3Treatment being tested
Participants will receive eloralintide SC
Treatment: Eloralintide
- Eloralintide Dose 4Treatment being tested
Participants will receive eloralintide SC
Treatment: Eloralintide
- PlaceboPlacebo, for comparison
Participants will receive placebo SC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
- Plain-language title
- Eloralintide weight loss study for adults with excess weight and type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026